RICHTER SYNDROME
Clinical trials for RICHTER SYNDROME explained in plain language.
Never miss a new study
Get alerted when new RICHTER SYNDROME trials appear
Sign up with your email to follow new studies for RICHTER SYNDROME, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug duo shows promise for hard-to-treat blood cancers
Disease control OngoingThis study tests a combination of two oral drugs, duvelisib and venetoclax, in 55 adults with relapsed or refractory chronic lymphocytic leukemia (CLL) or Richter's Syndrome. The goal is to see how well the drugs work together to shrink or control the cancer. Participants must ha…
Matched conditions: RICHTER SYNDROME
Phase: PHASE1, PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
New triple therapy aims to wipe out Hard-to-Treat leukemia
Disease control OngoingThis study tests a combination of three drugs—atezolizumab, obinutuzumab, and venetoclax—in about 50 adults with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma, or Richter syndrome that has returned or not responded to prior treatment. The goal is to see if the co…
Matched conditions: RICHTER SYNDROME
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 13, 2026 15:58 UTC
-
New combo therapy shows promise for Hard-to-Treat lymphoma
Disease control OngoingThis study tests a new drug called ALX148 combined with two standard treatments (rituximab and lenalidomide) for people with B-cell non-Hodgkin lymphoma that has not responded to prior therapy. The goal is to find the best dose and see if the combination can shrink or control the…
Matched conditions: RICHTER SYNDROME
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 08, 2026 12:00 UTC
-
New combo tackles tough blood cancers
Disease control OngoingThis early-phase study tests two drugs, pevonedistat and ibrutinib, together in people with chronic lymphocytic leukemia (CLL) or non-Hodgkin lymphoma that has returned or no longer responds to standard therapy. The main goal is to find the safest dose and understand side effects…
Matched conditions: RICHTER SYNDROME
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 04, 2026 16:32 UTC
-
New combo therapy targets tough blood cancers in early trial
Disease control OngoingThis early-phase study tests a combination of two drugs, copanlisib and nivolumab, in people with Richter's transformation or certain non-Hodgkin lymphomas. The goal is to find the safest dose and see how well the drugs work together. About 27 adults will take part, and the study…
Matched conditions: RICHTER SYNDROME
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 04, 2026 16:18 UTC
-
New combo tackles aggressive lymphoma that Won't quit
Disease control OngoingThis early-stage study tests a combination of four drugs (atezolizumab, gemcitabine, oxaliplatin, and rituximab) in about 24 people with a type of lymphoma that has come back or stopped responding to treatment. The main goals are to find the safest dose and see how well the drugs…
Matched conditions: RICHTER SYNDROME
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 04, 2026 16:17 UTC
-
Scientists dive deep into Epcoritamab's effects on blood cancers
Knowledge-focused OngoingThis study looks at blood, bone marrow, and lymph node samples from people with chronic lymphocytic leukemia (CLL) or Richter syndrome who are already receiving epcoritamab in another trial. The goal is to learn how the drug changes immune cells and cancer cells over time. Only 5…
Matched conditions: RICHTER SYNDROME
Phase: PHASE1 • Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Knowledge-focused
Last updated May 14, 2026 12:03 UTC